This Plain Language Summary of Publication article (PLSP) from Future Oncology compared a new nilotinib tablet (Danziten™, a solid compacted form of a medication) to the original capsule (Tasigna®, an outer shell, usually made of gelatin that contains the medication in powdered form) for treating chronic myeloid leukemia (CML).

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Pharmacokinetic profile of novel reduced-dose Danziten™ (nilotinib tablets) versus Tasigna® (nilotinib capsules): in vivo bioequivalence and population pharmacokinetic analysis’ and was published in Cancer Chemotherapy and Pharmacology.

Visit Springer Nature using the link to read the original article.